中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2015年
21期
126-130
,共5页
张尧%唐其柱%张宁%周梦桥
張堯%唐其柱%張寧%週夢橋
장요%당기주%장저%주몽교
卡维地洛%美托洛尔%扩张型心肌病%心力衰竭%Meta分析
卡維地洛%美託洛爾%擴張型心肌病%心力衰竭%Meta分析
잡유지락%미탁락이%확장형심기병%심력쇠갈%Meta분석
Carvediol%Metoprolo%Dilated cardiomyopathy%Heart failure%Meta-analysis
目的：评价美托洛尔和卡维地洛治疗扩张型心肌病心力衰竭的效果。方法检索中国生物医学文献数据库、中国知网、万方、维普、PubMed、Cochrane图书馆、EMbase中关于美托洛尔和卡维地洛治疗扩张型心肌病心力衰竭的随机对照试验，同时筛检纳入文献的参考文献，并对文献质量进行严格评价和资料提取，对符合质量标准的研究使用RevMan 5.1进行Meta分析。结果共纳入6篇文献，共438例患者。结果显示，与美托洛尔比较，卡维地洛治疗扩张型心肌病心力衰竭在临床有效率（OR =0.27，95%CI：0.15~0.48，P<0.00001）、左心室射血分数（MD=-3.10，95%CI：-4.75~-1.44，P=0.0002）、左心室舒张末期内径（MD=2.3，95%CI：0.89~3.71，P=0.001）方面具有良好的疗效，差异有统计学意义。结论卡维地洛可以改善扩张型心肌病心力衰竭的左心室射血分数、左心室舒张末期内径，提高临床有效率，值得推广。
目的：評價美託洛爾和卡維地洛治療擴張型心肌病心力衰竭的效果。方法檢索中國生物醫學文獻數據庫、中國知網、萬方、維普、PubMed、Cochrane圖書館、EMbase中關于美託洛爾和卡維地洛治療擴張型心肌病心力衰竭的隨機對照試驗，同時篩檢納入文獻的參攷文獻，併對文獻質量進行嚴格評價和資料提取，對符閤質量標準的研究使用RevMan 5.1進行Meta分析。結果共納入6篇文獻，共438例患者。結果顯示，與美託洛爾比較，卡維地洛治療擴張型心肌病心力衰竭在臨床有效率（OR =0.27，95%CI：0.15~0.48，P<0.00001）、左心室射血分數（MD=-3.10，95%CI：-4.75~-1.44，P=0.0002）、左心室舒張末期內徑（MD=2.3，95%CI：0.89~3.71，P=0.001）方麵具有良好的療效，差異有統計學意義。結論卡維地洛可以改善擴張型心肌病心力衰竭的左心室射血分數、左心室舒張末期內徑，提高臨床有效率，值得推廣。
목적：평개미탁락이화잡유지락치료확장형심기병심력쇠갈적효과。방법검색중국생물의학문헌수거고、중국지망、만방、유보、PubMed、Cochrane도서관、EMbase중관우미탁락이화잡유지락치료확장형심기병심력쇠갈적수궤대조시험，동시사검납입문헌적삼고문헌，병대문헌질량진행엄격평개화자료제취，대부합질량표준적연구사용RevMan 5.1진행Meta분석。결과공납입6편문헌，공438례환자。결과현시，여미탁락이비교，잡유지락치료확장형심기병심력쇠갈재림상유효솔（OR =0.27，95%CI：0.15~0.48，P<0.00001）、좌심실사혈분수（MD=-3.10，95%CI：-4.75~-1.44，P=0.0002）、좌심실서장말기내경（MD=2.3，95%CI：0.89~3.71，P=0.001）방면구유량호적료효，차이유통계학의의。결론잡유지락가이개선확장형심기병심력쇠갈적좌심실사혈분수、좌심실서장말기내경，제고림상유효솔，치득추엄。
Objective To review the efficacies of Carvediol and Metoprolo in treatment of dilated cardiomyopathy with heart failure. Methods The randomized controlled trials about the efficacies of Carvediol and Metoprolo in treatment of dilated cardiomyopathy with heart failure were retrieved from the databases of Chinese biomedical database, CNKI, Wanfang, VIP, PubMed, Cochrane library, EMbase. The references of enrolled literatures were screened, and the quality of references was evaluated strictly and the data was extracted, and then the studies met with the quality specification were taken a Meta-analysis by RevMan 5.1 software. Results Totally 6 references were included, 438 patients in total. The results showed that, compared with Metoprolo, the clinical effective rate (OR=0.27, 95%CI:0.15-0.48, P<0.000 01), left ventricular ejection fraction (MD=-3.10, 95%CI:-4.75 to-1.44, P=0.0002), left ventricular end-diastolic inner diameter (MD=2.3, 95%CI:0.89-3.71, P=0.001) in Carvediol group had good effects, the differences were statistical-ly significant. Conclusion Carvediol can significantly improve left ventricular ejection fraction and left ventricular end-diastolic inner diameter of dilated cardiomyopathy with heart failure, improve the clinical effective rate, which deserves promotion.
